CCKB/gastrin Receptor Antagonists: Recent Advances and Potential Uses in Gastric Secretory Disorders

Overview

Journal Yale J Biol Med

Specialty Biology

Date 1996 May 1

PMID 9165693

Citations 4

Authors

R T Jensen

Affiliations

Soon will be listed here.

Abstract

Cholecystokinin (CCK) and the structurally related peptide, gastrin, have numerous effects on tissues in the central nervous system and gastrointestinal tract. Recent studies show these effect are mediated by a CCKA and CCKB receptor. Knowledge of the physiological role and role of CCKB receptors in pathologic processes has been particularly limited by the availability of selective, potent receptor antagonists. Recently, new members of five different classes of non-peptide CCKB receptor antagonists are reported and are reviewed briefly. these include compounds isolated from Streptomyces (tetronothiodin, virginiamycin analogues), ureido-acetamide analogues (RP 69758, RP 72540, RP 73870), newer benzodiazepine analogues (L-368,935, L-740,093, YM022), pyrazolidimine analogues (LY 262,691) and glutamic acid analogues (CR2194). Many of these compounds have greater than 1000-fold selectivity for the CCKB over the CCKA receptor and some have greater than 10,000-fold selectivity. The pharmacology and effects of CCKB receptor antagonists on gastric acid secretion is briefly reviewed. Furthermore, the possible clinical usefulness of CCKB receptor antagonists in treating disorders of gastric acid secretion, in inhibiting the trophic effects of gastrin and in other clinical conditions is briefly discussed.

Citing Articles

Spirotetronate polyketides as leads in drug discovery.

Lacoske M, Theodorakis E J Nat Prod. 2014; 78(3):562-75.

PMID: 25434976 PMC: 4380204. DOI: 10.1021/np500757w.

Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Berna M, Tapia J, Sancho V, Jensen R Curr Opin Pharmacol. 2007; 7(6):583-92.

PMID: 17997137 PMC: 2186776. DOI: 10.1016/j.coph.2007.09.011.

Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Berna M, Jensen R Curr Top Med Chem. 2007; 7(12):1211-31.

PMID: 17584143 PMC: 2718729. DOI: 10.2174/156802607780960519.

Pharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cells.

Lindstrom E, Bjorkqvist M, Hakanson R Br J Pharmacol. 1999; 127(2):530-6.

PMID: 10385255 PMC: 1566020. DOI: 10.1038/sj.bjp.0702538.

References

Beinborn M, Lee Y, McBride E, Quinn S, Kopin A . A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature. 1993; 362(6418):348-50. DOI: 10.1038/362348a0. View

Lee Y, Beinborn M, McBride E, Lu M, Kolakowski Jr L, Kopin A . The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem. 1993; 268(11):8164-9. View

Qian J, Rowley W, Jensen R . Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors. Am J Physiol. 1993; 264(4 Pt 1):G718-27. DOI: 10.1152/ajpgi.1993.264.4.G718. View

Lamberts R, Creutzfeldt W, Struber H, Brunner G, Solcia E . Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104(5):1356-70. DOI: 10.1016/0016-5085(93)90344-c. View

Delvalle J, Chiba T, Park J, Yamada T . Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells. Am J Physiol. 1993; 264(5 Pt 1):G811-5. DOI: 10.1152/ajpgi.1993.264.5.G811. View

Gu Z, Rossowski W, Coy D, PRADHAN T, Jensen R . Chimeric galanin analogs that function as antagonists in the CNS are full agonists in gastrointestinal smooth muscle. J Pharmacol Exp Ther. 1993; 266(2):912-8. View

Harro J, Vasar E, Bradwejn J . CCK in animal and human research on anxiety. Trends Pharmacol Sci. 1993; 14(6):244-9. DOI: 10.1016/0165-6147(93)90020-k. View

Bradwejn J . Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci. 1993; 18(4):178-88. PMC: 1188527. View

Murphy M, Sytnik B, Kovacs T, Mertz H, Ewanik D, Shingo S . The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther. 1993; 54(5):533-9. DOI: 10.1038/clpt.1993.185. View

10.

Hocker M, Hughes J, Folsch U, Schmidt W . PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. Eur J Pharmacol. 1993; 242(1):105-8. DOI: 10.1016/0014-2999(93)90016-b. View

11.

Kuwahara T, Kudoh T, Nakano A, Yoshizaki H, Takamiya M, Nagase H . Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett. 1993; 158(1):1-4. DOI: 10.1016/0304-3940(93)90597-e. View

12.

Tang L, Miller M, Goldenring J, Modlin I, Hersey S . Partial agonism by gastrin for a cholecystokinin receptor mediating pepsinogen secretion. Am J Physiol. 1993; 265(5 Pt 1):G865-72. DOI: 10.1152/ajpgi.1993.265.5.G865. View

13.

Schmassmann A, Garner A, Flogerzi B, Hasan M, Sanner M, Varga L . Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut. 1994; 35(2):270-4. PMC: 1374507. DOI: 10.1136/gut.35.2.270. View

14.

Showell G, Bourrain S, Neduvelil J, Fletcher S, Baker R, Watt A . High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem. 1994; 37(6):719-21. DOI: 10.1021/jm00032a002. View

15.

Bock M, DiPardo R, Mellin E, Newton R, Veber D, Freedman S . Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem. 1994; 37(6):722-4. DOI: 10.1021/jm00032a003. View

16.

Metz D, Strader D, Orbuch M, Koviack P, Feigenbaum K, Jensen R . Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993; 7(6):597-610. DOI: 10.1111/j.1365-2036.1993.tb00140.x. View

17.

Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A . Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1994; 269(2):725-31. View

18.

Bohme G, Bertrand P, Guyon C, Capet M, Pendley C, Stutzmann J . The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann N Y Acad Sci. 1994; 713:118-20. DOI: 10.1111/j.1749-6632.1994.tb44057.x. View

19.

Freedman S, Patel S, Smith A, Chapman K, Fletcher A, Kemp J . A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential. Ann N Y Acad Sci. 1994; 713:312-8. DOI: 10.1111/j.1749-6632.1994.tb44079.x. View

20.

Patel S, Chapman K, Smith A, Heald A, Freedman S . Use of ex vivo binding to estimate brain penetration and central activity of CCK-B antagonists. Ann N Y Acad Sci. 1994; 713:360-3. DOI: 10.1111/j.1749-6632.1994.tb44093.x. View